ADMA Biologics Inc. (NASDAQ: ADMA) started the day on July 14, 2021, with a price decrease of 0.00% at $1.45. During the day, the stock rose to $1.505 and sunk to $1.43 before settling in for the price of $1.45 at the close. Taking a more long-term approach, ADMA posted a 52-week range of $1.38-$4.20.The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 42.50%. Meanwhile, its Annual Earning per share during the time was 12.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 1.00%. This publicly-traded company’s shares outstanding now amounts to $115.66 million, simultaneously with a float of $104.02 million. The organization now has a market capitalization sitting at $177.19 million. At the time of writing, stock’s 50-day Moving Average stood at $1.6870, while the 200-day Moving Average is $2.0256.
It is imperative to bring your focus towards the efficiency factor of the conglomerate that has a total of 406 employees. It has generated 103,734 per worker during the last fiscal year. Meanwhile, its income per employee was -186,114. The stock had 5.05 Receivables turnover and 0.25 Total Asset turnover. For the Profitability, stocks gross margin was -46.87, operating margin was -153.75 and Pretax Margin of -179.41.
ADMA Biologics Inc. (ADMA) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. ADMA Biologics Inc.’s current insider ownership accounts for 0.50%, in contrast to 41.90% institutional ownership. According to the most recent insider trade that took place on Sep 11, this organization’s Director bought 2,200 shares at the rate of 2.29, making the entire transaction reach 5,038 in total value, affecting insider ownership by 4,200. Preceding that transaction, on Sep 10, Company’s Director bought 5,000 for 2.22, making the whole transaction’s value amount to 11,100. This particular insider is now the holder of 160,864 in total.
ADMA Biologics Inc. (ADMA) Earnings and Revenue Records
This company achieved a net margin of -179.41 while generating a return on equity of -132.38.
ADMA Biologics Inc.’s EPS increase for this current 12-month fiscal period is 1.00% and is forecasted to reach -0.34 in the upcoming year.
ADMA Biologics Inc. (NASDAQ: ADMA) Trading Performance Indicators
Let’s observe the current performance indicators for ADMA Biologics Inc. (ADMA). It’s Quick Ratio in the last reported quarter now stands at 3.90. The Stock has managed to achieve an average true range (ATR) of 0.07. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.68.
In the same vein, ADMA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.79, a figure that is expected to reach -0.15 in the next quarter, and analysts are predicting that it will be -0.34 at the market close of one year from today.
Technical Analysis of ADMA Biologics Inc. (ADMA)
If we take a close look at the recent performances of ADMA Biologics Inc. (NASDAQ: ADMA), its last 5-days Average volume was 1.81 million that shows plunge from its year to date volume of 5.18 million. During the previous 9 days, stock’s Stochastic %D was recorded 26.11% While, its Average True Range was 0.0742.
Raw Stochastic average of ADMA Biologics Inc. (ADMA) in the period of the previous 100 days is set at 5.60%, which indicates a major fall in contrast to 18.92% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 40.58% that was lower than 60.26% volatility it exhibited in the past 100-days period.